cDNA Cloning and Functional Analysis of Minipig Uridine Diphosphate-

Yuuka Miyake,a Kei Mayumi,a Hideto Jinno,b Toshiko Tanaka-Kagawa,b Shizuo Narimatsu,a and Nobumitsu Hanioka*,a a Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University; 1–1–1 Tsushimanaka, Kita-ku, Okayama 700–8530, Japan: and b Division of Environmental Chemistry, National Institute of Health Sciences; 1–18–1 Kamiyoga, Setagaya-ku, Tokyo 158–8501, Japan. Received November 11, 2012; accepted December 27, 2012

[1]  P. Gervasi,et al.  Xenobiotic metabolizing cytochrome P450 in pig, a promising animal model. , 2011, Current drug metabolism.

[2]  T. Tracy,et al.  Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors , 2011, Drug Metabolism and Disposition.

[3]  J. Sims,et al.  The utility of the minipig as an animal model in regulatory toxicology. , 2010, Journal of pharmacological and toxicological methods.

[4]  H. Jinno,et al.  Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. , 2010, Life sciences.

[5]  A. Sparreboom,et al.  Pharmacogenetics of irinotecan disposition and toxicity: a review. , 2010, Current clinical pharmacology.

[6]  C. Guillemette,et al.  UGT genomic diversity: beyond gene duplication , 2009, Drug metabolism reviews.

[7]  M. Zečević,et al.  Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma. , 2009, Journal of pharmaceutical and biomedical analysis.

[8]  Shuji Ohno,et al.  Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2009, Drug Metabolism and Disposition.

[9]  P. Anzenbacher,et al.  Interspecies comparison of the glucuronidation processes in the man, monkey, pig, dog and rat. , 2008, Neuro endocrinology letters.

[10]  H. Jinno,et al.  Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A6 enzymes. , 2006, Chemico-biological interactions.

[11]  S. Nagar,et al.  Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan , 2006, Drug metabolism reviews.

[12]  C. Guillemette,et al.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.

[13]  P. Souček,et al.  MINIPIG CYTOCHROME P450 2E1: COMPARISON WITH HUMAN ENZYME , 2005, Drug Metabolism and Disposition.

[14]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[15]  P. Souček,et al.  Model systems based on experimental animals for studies on drug metabolism in man: (mini)pig cytochromes P450 3A29 and 2E1. , 2005, Basic & clinical pharmacology & toxicology.

[16]  Michael H Court,et al.  Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. , 2005, Methods in enzymology.

[17]  S. Zeng,et al.  Direct determination of S-(-)- and R-(+)-propranolol glucuronide in rat hepatic microsomes by RP-HPLC. , 2004, Biomedical chromatography : BMC.

[18]  Olivier Bernard,et al.  The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[19]  K. Muro,et al.  Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. , 2004, Biochemical pharmacology.

[20]  T. Kamataki,et al.  Cloning CYP2D21 and CYP3A22 cDNAs from liver of miniature pigs. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[21]  A. Galetin,et al.  Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[22]  R. Iannucci,et al.  Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[23]  D. Greenblatt,et al.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[24]  P. A. Gregory,et al.  Regulation of UDP glucuronosyltransferase genes. , 2003, Current drug metabolism.

[25]  M. Shimizu,et al.  Glucuronidation of propofol and its analogs by human and rat liver microsomes. , 2003, Biological & pharmaceutical bulletin.

[26]  C. Guillemette.  Pharmacogenomics of human UDP-glucuronosyltransferase enzymes , 2003, The Pharmacogenomics Journal.

[27]  David J Greenblatt,et al.  Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[28]  R. Frye,et al.  Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3- and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[29]  P. Souček,et al.  Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs , 2001, BMC pharmacology.

[30]  Yoshiro Saito,et al.  Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[31]  J. Ritter.  Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. , 2000, Chemico-biological interactions.

[32]  S. Wrighton,et al.  Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. , 2000, Pharmacogenetics.

[33]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[34]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[35]  T. Iyanagi,et al.  Biochemical and molecular aspects of genetic disorders of bilirubin metabolism. , 1998, Biochimica et biophysica acta.

[36]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[37]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[38]  M. Andersen,et al.  Interspecies Scaling in Pharmacokinetics , 1991 .

[39]  M. Khan.  Minipig: Advantages and Disadvantages as a Model in Toxicity Testing , 1984 .